Lv4
644 积分 2025-06-26 加入
Clinical Cytokine Assays Early in the Course of Cytokine Release Syndrome (CRS) after CAR-T Therapy Show Difference Among Patients with Severe CRS Versus Immune Effector Cell-Associated Hemophagocytic Syndrome (IEC-HS)
1个月前
已完结
How I treat HLH-like toxicities after immune effector cell therapy
1个月前
已关闭
Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial
1个月前
已完结
Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial
1个月前
已完结
Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial
2个月前
已完结
Engineering challenges and translational opportunities in emerging gene delivery platforms
2个月前
已完结
Tumor-intrinsic regulators of the immune-cold microenvironment of prostate cancer
4个月前
已完结
Prostate cancer
4个月前
已完结
mRNA lipid nanoparticle formulation, characterization and evaluation
4个月前
已完结
Preparation of targeted lipid nanoparticles for precision nucleic acid delivery
4个月前
已完结
皖公网安备34019202002308
